J Korean Diabetes.  2022 Sep;23(3):192-200. 10.4093/jkd.2022.23.3.192.

Alcohol Drinking, Smoking, and Diabetes

• Jung W

• KMID: 2534305
• DOI: http://doi.org/10.4093/jkd.2022.23.3.192

Abstract

Many patients with diabetes continue smoking and high-risk drinking during diabetes treatment. Some patients try and fail to stop alcohol drinking and smoking because of the addictive and habitual effects. Considering the high lifetime prevalence of alcohol and nicotine use disorders, the percentage of people who actively use treatment services is low. Smoking is related to increased vascular complications and mortality as well as development of diabetes. A small amount of alcohol is allowed in the diabetes treatment guidelines, but the limit can be difficult to maintain in reality. Therefore, it is necessary for a medical doctor to evaluate the alcohol and smoking problems of diabetic patients, and it may be helpful to use screening and evaluation tools such as AUDIT (alcohol use disorders identification test) for alcohol drinking and FTND (Fagerstrom Test for Nicotine Dependence) for smoking. It is important that patients are provided necessary information and a brief intervention and that they are recommended a professional treatment such as active treatment with anti-craving medications and structural psychosocial treatment programs. Many patients are worried about the harmful effects of alcohol drinking and smoking and think they should quit it, but at the same time, they may have their own reasons for not being able to quit drinking and smoking, and may be suffering from ambivalent ideas about alcohol drinking and smoking. Therefore, rather than criticizing the patient’s alcohol drinking and smoking behavior, it is important to show understanding of patient difficulties and to encourage the patient to stop drinking and smoking.

Keyword

Alcohol drinking; Diabetes mellitus; Nicotine; Smoking

Reference

1.American Diabetes Association. Implications of the Unit-ed Kingdom prospective diabetes study. Diabetes Care. 2000. 23(Suppl 1):S27–31.

2.Chung JH., Kim OS. Alcohol consumption and cigarette smoking in men with diabetes mellitus. Korean J Adult Nurs. 2005. 17:68–76.

3.Korean Diabetes Association. Diabetes fact sheet in Korea 2020. Seoul: Korean Diabetes Association;2020.

4.National Center for Mental Health; Ministry of Health and Welfare. National mental health survey 2021. Seoul: National Center for Mental Health;2021.

5.Evert AB., Dennison M., Gardner CD., Garvey WT., Lau KHK., MacLeod J, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019. 42:731–54.

6.Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. Circulation. 2016. 133:187–225.

7.Wei M., Gibbons LW., Mitchell TL., Kampert JB., Blair SN. Alcohol intake and incidence of type 2 diabetes in men. Diabetes Care. 2000. 23:18–22.

8.Facchini F., Chen YD., Reaven GM. Light-to-moderate al-cohol intake is associated with enhanced insulin sensitivi-ty. Diabetes Care. 1994. 17:115–9.

9.Korean Diabetes Association. Clinical practice guidelines for diabetes. 7th ed.Seoul: Korean Diabetes Association;2021.

10.Engler PA., Ramsey SE., Smith RJ. Alcohol use of diabetes patients: the need for assessment and intervention. Acta Diabetol. 2013. 50:93–9.

11.Beulens JW., Kruidhof JS., Grobbee DE., Chaturvedi N., Fuller JH., Soedamah-Muthu SS. Alcohol consumption and risk of microvascular complications in type 1 diabetes patients: the EURODIAB Prospective Complications Study. Diabetologia. 2008. 51:1631–8.

12.Shai I., Rimm EB., Schulze MB., Rifai N., Stampfer MJ., Hu FB. Moderate alcohol intake and markers of inflammation and endothelial dysfunction among diabetic men. Diabetologia. 2004. 47:1760–7.

13.Yuan JM., Govindarajan S., Arakawa K., Yu MC. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer. 2004. 101:1009–17.

14.Śliwińska-Mossoń M., Milnerowicz H. The impact of smoking on the development of diabetes and its complications. Diab Vasc Dis Res. 2017. 14:265–76.

15.Qin R., Chen T., Lou Q., Yu D. Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: meta-analysis of observational prospective studies. Int J Cardiol. 2013. 167:342–50.

16.Martín-Timón I., Sevillano-Collantes C., Segura-Galindo A., Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014. 5:444–70.

17.Hsu CC., Hwang SJ., Tai TY., Chen T., Huang MC., Shin SJ, et al. Cigarette smoking and proteinuria in Taiwanese men with Type 2 diabetes mellitus. Diabet Med. 2010. 27:295–302.

18.Korean Academy of Addiction Psychiatry. Addiction Psychiatry. 2nd ed.Seoul: iMiS Company;2021.

19.Ebbert JO., Patten CA., Schroeder DR. The Fagerström Test for Nicotine Dependence-smokeless tobacco (FT-ND-ST). Addict Behav. 2006. 31:1716–21.

20.Korean Academy of Addiction Psychiatry. Addiction treatment guidelines. Changnyeong: Korean Academy of Addiction Psychiatry;2011.

21.Mann K., Kiefer F., Smolka M., Gann H., Wellek S., Heinz A; PREDICT Study Research Team. Searching for re-sponders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study. Alcohol Clin Exp Res. 2009. 33:674–83.

22.Reus VI., Fochtmann LJ., Bukstein O., Eyler AE., Hilty DM., Horvitz-Lennon M, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018. 175:86–90.

23.Rosenthal RN., Gage A., Perhach JL., Goodman AM. Acamprosate: safety and tolerability in the treatment of alcohol dependence. J Addict Med. 2008. 2:40–50.

24.Kennedy WK., Leloux M., Kutscher EC., Price PL., Morstad AE., Carnahan RM. Acamprosate. Expert Opin Drug Me-tab Toxicol. 2010. 6:363–80.

25.Park SW. Evidence-based smoking cessation counseling: motivational intervention and relapse prevention. J Korean Med Assoc. 2011. 54:1036–46.

26.Barua RS., Rigotti NA., Benowitz NL., Cummings KM., Jazayeri MA., Morris PB, et al. 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2018. 72:3332–65.

27.Hwang JS., Lee CM. Recent updates of pharmacotherapy for smoking cessation. Korean J Fam Pract. 2021. 11:403–14.

28.Gómez-Coronado N., Walker AJ., Berk M., Dodd S. Cur-rent and emerging pharmacotherapies for cessation of tobacco smoking. Pharmacotherapy. 2018. 38:235–58.

29.Hays JT., Ebbert JO. Varenicline for tobacco dependence. N Engl J Med. 2008. 359:2018–24.

30.Faessel HM., Obach RS., Rollema H., Ravva P., Williams KE., Burstein AH. A review of the clinical pharmacoki-netics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet. 2010. 49:799–816.

31.U.S. Food and Drug Administration. FDA updates and press announcements on nitrosamine in varenicline (Chantix). Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-an-nouncements-nitrosamine-varenicline-chantix (updated 2022 May 5).

32.Project MATCH (Matching Alcoholism Treatment to Cli-ent Heterogeneity): rationale and methods for a multisite clinical trial matching patients to alcoholism treatment. Alcohol Clin Exp Res. 1993. 17:1130–45.

33.Joe KH. Treatment of the alcohol use disorder at outpatient psychiatric clinic. J Korean Neuropsychiatr Assoc. 2019. 58:159–66.

34.Nowinski J., Baker S., Carroll K. Twelve step facilitation therapy manual: a clinical research guide for therapists treating individuals with alcohol abuse and dependence. Rockville: U.S. Department of Health and Human Ser-vices;1992.